Literature DB >> 8378826

Radiation injuries of the colon and rectum.

D P Otchy1, H Nelson.   

Abstract

Approximately 5% to 10% of patients receiving abdominopelvic radiation therapy will develop a colon or rectal injury. Thorough evaluation of the patient to determine the extent of the injury and the presence of concomitant lesions and to rule out recurrent malignancy is urged. Many radiation complications can be managed with medical regimens. Although colostomy remains a valuable and frequently utilized mode of treatment, it is by no means the sole alternative when surgical intervention is required. Rectal resection with colorectal or coloanal anastomosis can be performed safely for some injuries involving the distal rectum. Surgery for irradiated bowel should be focused on minimizing dissection to minimize injuries and on providing healthy non-irradiated tissues to provide adequate blood supply to promote healing. Patients who have received abdominopelvic radiation are at greater risk of developing colorectal cancer, and cancer surveillance should be commenced 5 years after completion of therapy.

Entities:  

Mesh:

Year:  1993        PMID: 8378826     DOI: 10.1016/s0039-6109(16)46138-4

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  3 in total

1.  Pharmacotherapy for chronic hemorrhagic radiation proctitis.

Authors:  Yunus A Gul; Subhita Prasannan; Faisal M Jabar; Abdul R H Shaker; Kevin Moissinac
Journal:  World J Surg       Date:  2002-09-26       Impact factor: 3.352

2.  Rectal inflammation as first manifestation of graft-vs-host disease: radiologic-pathologic findings.

Authors:  Vito Cantisani; Koenraad J Mortele; Salvatore G Viscomi; Jonathan Glickman; Stuart G Silverman; Pablo R Ros
Journal:  Eur Radiol       Date:  2003-01-17       Impact factor: 5.315

3.  Formalin application for the treatment of radiation-induced hemorrhagic proctitis.

Authors:  Sun-Il Lee; Yoon-Ah Park; Seung-Kook Sohn
Journal:  Yonsei Med J       Date:  2007-02-28       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.